EMA, MIT Form Research Project for Regulatory Science - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA, MIT Form Research Project for Regulatory Science


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency (EMA) and the Massachusetts Institute of Technology’s (MIT's) Center for Biomedical Innovation (CBI) and Center for International Studies (CIS) are launching a collaborative research project with a focus on enhancing regulatory science in pharmaceuticals, according to an EMA press release.  

The project, which is scheduled to be completed by December 2011, will be conducted within the framework of CBI’s New Drug Development Paradigms (NEWDIGS) research program in cooperation with EMA and CIS. The project will address the following specific questions:

• How to adapt current regulatory requirements to support the efficient development of safe and effective drugs

• How to incorporate patient valuation of health outcomes and benefit–risk preferences into regulatory decision-making

• How to implement “staggered and progressive” approaches to drug approval

• How to improve the fulfillment of postmarketing regulatory requirements. 

The data and recommendations from this project are expected to link to the implementation of EMA’s Roadmap to 2015, a plan for the agency's strategic development for the next five years, and to the NEWDIGS research program. The project will explore the feasibility of, priorities for, and practical considerations of implementing demonstration projects on some of the issues addressed during the course of the research.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here